Question to the Department of Health and Social Care:

To ask His Majesty's Government, given that NHS England’s 2023 guidance Liothyronine – advice for prescribers sets out a complete national prescribing pathway without including any requirement for local prior approval processes, if local prior approval was not included because it is not required.

NHS England’s policy guidance and prescribing advice on liothyronine reflects the National Institute for Health and Care Excellence’s recommendations and the evidence on liothyronine. That guidance recommends that liothyronine should not be routinely prescribed, because it is not clinically or cost-effective, but sets out the exceptions where it may be an appropriate consideration for prescribers.

NHS England expects commissioners and prescribers to have due regard to its guidance. While integrated care boards may determine their own implementation arrangements, as part of the new operating model, regions will oversee commissioner and provider performance, including access to high quality care and the reduction of health inequalities.